0001209191-18-004394.txt : 20180118
0001209191-18-004394.hdr.sgml : 20180118
20180118185755
ACCESSION NUMBER: 0001209191-18-004394
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180116
FILED AS OF DATE: 20180118
DATE AS OF CHANGE: 20180118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Doogan Declan
CENTRAL INDEX KEY: 0001704234
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38080
FILM NUMBER: 18535103
MAIL ADDRESS:
STREET 1: C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP
STREET 2: 234 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd.
CENTRAL INDEX KEY: 0001689813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 234 CHURCH STREET, SUITE 304
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 234 CHURCH STREET, SUITE 304
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-16
0
0001689813
Biohaven Pharmaceutical Holding Co Ltd.
BHVN
0001704234
Doogan Declan
C/O BIOHAVEN PHARMACEUTICALS
234 CHURCH STREET
NEW HAVEN
CT
06510
1
0
0
0
Common Shares
2018-01-16
4
S
0
37033
26.59
D
1487027
I
By The Declan Doogan 2014 Trust
Common Shares
2018-01-16
4
S
0
1834
27.07
D
1485193
I
By The Declan Doogan 2014 Trust
Common Shares
2018-01-17
4
S
0
23726
26.19
D
1461467
I
By The Declan Doogan 2014 Trust
Common Shares
2018-01-17
4
S
0
37530
26.84
D
1423937
I
By The Declan Doogan 2014 Trust
Common Shares
2018-01-18
4
S
0
4546
26.71
D
1419391
I
By The Declan Doogan 2014 Trust
Common Shares
2018-01-18
4
S
0
5618
27.87
D
1413773
I
By The Declan Doogan 2014 Trust
Common Shares
2018-01-18
4
S
0
17671
28.71
D
1396102
I
By The Declan Doogan 2014 Trust
Common Shares
2018-01-18
4
S
0
100
29.22
D
1396002
I
By The Declan Doogan 2014 Trust
Common Shares
463913
D
These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 - $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Includes 346,002 shares received by the Reporting Person from by Portage Biotech Inc. as a distribution in kind on a pro rata basis to its shareholders, effective January 15, 2017, which transaction was not required to be reported under SEC rules (the "Distribution").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 - $27.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.64 - $26.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.64 - $27.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 - $26.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.20 - $28.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.21 - $29.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) to this Form 4.
Represents shares received directly by the Reporting Person in the Distribution.
/s/ Darren K. DeStefano, Attorney-in-fact
2018-01-18